Through the lens of phosphorus: The legacy of Andrew Sharpley.

The pursuit of sustainable phosphorus (P) management represents a long-standing challenge in agricultural arenas, with far-reaching implications for the environment and societal development. Few scholars are as synonymous with P science as Andrew Sharpley. Renowned over his 44-year professional career for providing foundational insights into the fate and management of agricultural P, Sharpley also became the central figure in organizing responses to concerns over the contribution of non-point source P pollution to eutrophication.

Effect of P rates in long-term conservation agriculture trials on the vertical distribution of soil acidity and nutrient availability.

Few studies are published on the long-term impact of phosphorus (P) rates as triple superphosphate (208 g P kg) on the vertical distribution of soil acidity and the availability of macro and micronutrients within conservation systems. This study explores the long-term impacts of increasing P rates on the vertical distribution of soil acidity and Mehlich-3 nutrient availability in long-term trials managed under conservation tillage in North Carolina. In 2022, soil samples were collected from two contrasting long-term trials: one on a sandy, poorly drained Portsmouth soil at Tidewater Research Station (67 years) and another on a well-drained, clay-rich Lloyd soil at Piedmont Research Station (37 years), at depths of 0-5, 5-10, 10-20, and 20-30 cm.

Leveraging the genetic diversity of trout in the rivers of the British Isles and northern France to understand the movements of sea trout ( L.) around the English Channel.

Populations of anadromous brown trout, also known as sea trout, have suffered recent marked declines in abundance due to multiple factors, including climate change and human activities. While much is known about their freshwater phase, less is known about the species' marine feeding migrations. This situation is hindering the effective management and conservation of anadromous trout in the marine environment.

Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A.

Introduction: Valoctocogene roxaparvovec is an adeno-associated virus vector serotype 5 (AAV5)-mediated gene therapy approved for severe haemophilia A (HA).

Aim: To report the safety and efficacy of valoctocogene roxaparvovec 7 years after dosing in a phase 1/2 clinical study (NCT02576795).

Methods: Males ≥18 years with severe HA (factor VIII [FVIII] ≤1 international unit [IU]/dL) who were previously receiving exogenous FVIII and had no history of FVIII inhibitors or anti-AAV5 antibodies received valoctocogene roxaparvovec treatment and were followed for 7 (6 × 10 vg/kg; n = 7) and 6 (4 × 10 vg/kg; n = 6) years.

Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A.

Introduction: Valoctocogene roxaparvovec, a gene therapy evaluated in the phase 3 GENEr8-1 trial, supports endogenous factor VIII (FVIII) production to prevent bleeding in people with severe haemophilia A. Individuals receiving emicizumab, an antibody mimicking the function of activated FVIII, were excluded from GENEr8-1 enrolment since emicizumab was an investigational therapy at the time of trial initiation.

Aim: Utilize pharmacokinetic simulations to provide guidance on best practices for maintaining haemostatic control while transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec.